Here we have also demonstrated the efficacy of targeting ERG with SSOs in vivo using xenograft models and ex vivo using patient-derived PCa tumour samples, supporting the approach of targeting an oncogene with SSOs, as others have also previously shown.42,43 Mouse xenograft models using the ERG-positive MG63 cell line exhibited reduced tumour growth upon systemic E43′ SSO treatment, accompanied by reduced ERG protein levels in treated tumours harvested from the mice at the study’s conclusion. The gene discussed is ERG; the disease is neoplasm.